Bellerophon to Present Positive Results from Phase 2 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease at the American Thoracic Society 114th International Conference
May 16, 2018 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., May 16, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it will...
Bellerophon Provides Business Update and Reports First Quarter 2018 Financial Results
May 10, 2018 08:45 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business...
Bellerophon Reaches Agreement with FDA on Study Design of Phase 2b Trial of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease
May 08, 2018 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., May 08, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that,...
Bellerophon Therapeutics to Provide Corporate Update at H.C. Wainwright Annual Global Life Sciences Conference
April 03, 2018 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., April 03, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that Fabian...
Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
March 15, 2018 16:45 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., March 15, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business...
Bellerophon Therapeutics Announces Enrollment Exceeds 100 Patients in Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension
January 29, 2018 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that enrollment in its Phase 3 INOvation-1...
Bellerophon Announces First Patient Enrolled in Phase 2b Study Evaluating INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
January 03, 2018 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that the first patient has been randomized...
Bellerophon Appoints Ted Wang, Ph.D., of Puissance Capital Management, to its Board of Directors
November 30, 2017 17:46 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the appointment of Ted Wang, Ph.D., Chief...
Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results
November 07, 2017 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial...
Bellerophon Announces $23 Million Private Placement
September 27, 2017 08:30 ET
|
Bellerophon Therapeutics Inc.
Financing will support the continued development of the company’s INOpulse platform with Phase 3 clinical trials in Pulmonary Arterial Hypertension and Phase 2 trials in Pulmonary Hypertension...